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The bleeding edge
To the Editor: We read with great interest the study by Ebrahim et al.[1] 
in the June SAMJ, titled ‘Poor anticoagulation control in patients taking 
warfarin at a tertiary and district-level prothrombin clinic in Cape 
Town, South Africa’. This was a retrospective review of anticoagulation 
control in patients taking warfarin at two international normalised 
ratio (INR) monitoring centres in Cape Town. The authors found that 
time in the therapeutic range (TTR), which reflects the time in which 
the patient’s INR was within the desired range, was remarkably low, 
at a mean of 47%. For anticoagulation to be effective, the accepted 
TTR is >65%. A post hoc analysis of the multicentre ACTIVE-W 
trial that looked at patients with atrial fibrillation (AF) treated with 
either warfarin or dual antiplatelet therapy identified a threshold 
TTR range for therapeutic efficacy of oral anticoagulants (OACs) of 
58 - 65%, below which OACs were no better than platelet blockade. [2] 
Furthermore, an earlier subgroup analysis of combined data from 
the SPORTIF III and V trials looked at patients with AF randomised 
to warfarin. White et al.[3] found that poor INR control, defined as 
TTR of <60%, with a median of 48% (similar to the local data), was 
associated with a significant risk of complications including myocardial 
infarction and ischaemic and haemorrhagic stroke,[3] since time outside 
the therapeutic range includes both sub- and supratherapeutic levels.
Levels above the desired range are known to increase the risk of 
major bleeding, one of the complications of which is intracranial 
haemorrhage, a potentially devastating condition. At our neurosurgical 
centre, we see a steady number of patients every month with this 
complication. The most common presentations are intracerebral 
haematoma (ICH) and acute or chronic subdural haematomas. It 
is known that ICHs associated with warfarin anticoagulation are 
larger than spontaneous ICHs in non-warfarin users, tend to expand 
within 72 hours, and are associated with poorer prognosis in the 
form of either death or disability, with in-hospital mortality of up 
to 42%.[4-6] Treatment of these haematomas is compounded by the 
fact that numerous studies have shown that surgery fails to change 
this prognostic outcome.[7,8] Chronic subdural haematomas, which 
generally carry mortality between 1% and 3%, can be recurrent and 
when occurring in the elderly can have a mortality rate of up to 20 - 
32%.[9] It is reassuring then that Ebrahim and his colleagues[1] found a 
higher rate of TTR among older patients. Surgical treatment for these 
lesions is further hindered by the need to reverse what are sometimes 
remarkably high INRs, and there remains controversy over the best 
way to do this.
We have begun to look systematically at this patient population 
to better quantify this problem, and therefore wish to congratulate 
the authors on a very timely and appropriate study of relevance to 
multiple disciplines across a broad patient population. With the 
limited availability of alternative anticoagulants, a discussion on 
how to improve our anticoagulation monitoring to better protect 
our patients against life-threatening complications is overdue. And 
if we cannot improve our mean TTR, should we consider platelet 
inhibition instead for conditions such as AF, or should healthcare 
funders make alternatives like direct thrombin inhibitors more 
available to the state?
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